US EditionPublished • loading... • Updated
Actinogen Medical Clears Interim DMC Review for XanaMIA Alzheimer’s Trial, Unveils AUD 12M Raise
Summary by watchlistnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Actinogen Medical Clears Interim DMC Review for XanaMIA Alzheimer’s Trial, Unveils AUD 12M Raise
Actinogen Medical (ASX:ACW) said an independent Data Monitoring Committee (DMC) has recommended its ongoing XanaMIA pivotal trial of Xanamem in mild-to-moderate Alzheimer’s disease continue without changes, following an interim safety and efficacy/futility review. Company executives said the outcome increases their confidence ahead of planned topline results in November, while also outlining a new equity raising […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
